BUG-BUSTING company Byotrol haverevealed test results showing that its pioneering liquid could help hospitals win the war against the infections such as MRSA.

Bosses at the Collyhurst-based firm unveiled the results of a study at Glasgow Royal Infirmary at an international medical conference in Holland, which showed that Byotrol can slash the incidence of MRSA on hospital wards.

The six-month study at GRI was staged in two vascular surgery wards at the hospital, with potential for high incidence of MRSA infection.

One of the wards was cleaned with Byotrol and the other with existing cleaning fluids.

The independently-supervised study showed that daily cleaning with Byotrol of the ward's high contact surfaces, such as door handles, tables, TV handsets, and bed rails, representing a small fraction of the total surfaces within the ward, resulted in a significant reduction in the incidence of MRSA.

The cleaning regime, which required no special equipment or extra resources, was practised for four months and the incidence of MRSA was shown to have been reduced by 75 per cent against the pre-trial condition of the ward.

During this phase there were test periods with no incidence of MRSA and the number of hospital acquired cases of MRSA was 50 per cent higher where a conventional disinfectant was used compared to the area treated with Byotrol.

The study was independently supervised by Professor Curtis Gemmell, Professor of Bacterial Infection and Epidemiology at the University of Glasgow and an expert in MRSA research.

Professor Gemmell presented a paper based on the study to medical and infection control professionals at the 6th international conference of the Hospital Infection Society in Holland.

Stephen Falder, Byotrol's founder and deputy chairman commented: "We are very, very pleased and excited. This independent study has demonstrated the outstanding effectiveness of Byotrol in a working hospital environment.

"Byotrol was used by the cleaning staff, with no risk or disturbance to patients or healthcare professionals and with no requirement for expensive equipment."

He said Byotrol was not substantially more expensive than existing disinfectants on the market.

"We have to make sure there are no obstacles to those in the healthcare sector with budgets to stick to."